{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:41:31Z","timestamp":1789810891634,"version":"4.0.1"},"reference-count":97,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":173,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.drudis.2023.103617","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T17:28:51Z","timestamp":1684171731000},"page":"103617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Targeting hepatitis B virus cccDNA levels: Recent progress in seeking small molecule drug candidates"],"prefix":"10.1016","volume":"28","author":[{"given":"Yu","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangrui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasanthanathan","family":"Poongavanam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Men\u00e9ndez-Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1156-1036","authenticated-orcid":false,"given":"Peng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2023.103617_b0005","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.idc.2019.08.004","article-title":"Viral hepatitis: etiology, epidemiology, transmission, diagnostics, treatment, and prevention","volume":"33","author":"Lanini","year":"2019","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.drudis.2023.103617_b0010","doi-asserted-by":"crossref","first-page":"e00560","DOI":"10.1128\/AAC.00560-17","article-title":"Capsid assembly modulators have a dual mechanism of action in primary human hepatocytes infected with hepatitis B virus","volume":"61","author":"Berke","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2023.103617_b0015","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.gastro.2018.10.048","article-title":"What is needed to eliminate hepatitis B virus and hepatitis C virus as global health threats","volume":"156","author":"Ward","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2023.103617_b0020","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2174\/187152607782110077","article-title":"Interaction and assembly of HBV structural proteins: novel target sites of anti-HBV agents","volume":"7","author":"Choi","year":"2007","journal-title":"Infect Disord Drug Targets"},{"key":"10.1016\/j.drudis.2023.103617_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104925","article-title":"Hepatitis B virus biology and life cycle","volume":"182","author":"Tsukuda","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2023.103617_b0030","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/hep.21896","article-title":"Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans","volume":"46","author":"Schulze","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2023.103617_b0035","doi-asserted-by":"crossref","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"Elife"},{"key":"10.1016\/j.drudis.2023.103617_b0040","doi-asserted-by":"crossref","first-page":"8487","DOI":"10.1073\/pnas.1811064116","article-title":"Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization","volume":"116","author":"Iwamoto","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2023.103617_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104999","article-title":"Ponesimod suppresses hepatitis B virus infection by inhibiting endosome maturation","volume":"186","author":"Fauzyah","year":"2021","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2023.103617_b0050","doi-asserted-by":"crossref","first-page":"9849","DOI":"10.1073\/pnas.1730940100","article-title":"Nuclear import of hepatitis B virus capsids and release of the viral genome","volume":"100","author":"Rabe","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2023.103617_b0055","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3390\/cells9092023","article-title":"Intracellular trafficking of HBV particles","volume":"9","author":"Jiang","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.drudis.2023.103617_b0060","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.virusres.2016.12.019","article-title":"Viral reverse transcriptases","volume":"234","author":"Men\u00e9ndez-Arias","year":"2017","journal-title":"Virus Res"},{"key":"10.1016\/j.drudis.2023.103617_b0065","doi-asserted-by":"crossref","first-page":"e1007124","DOI":"10.1371\/journal.ppat.1007124","article-title":"Flap endonuclease 1 is involved in cccDNA formation in the hepatitis B virus","volume":"14","author":"Kitamura","year":"2018","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.drudis.2023.103617_b0070","doi-asserted-by":"crossref","first-page":"e1005893","DOI":"10.1371\/journal.ppat.1005893","article-title":"DNA polymerase \u03ba is a key cellular factor for the formation of covalently closed circular DNA of hepatitis B virus","volume":"12","author":"Qi","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.drudis.2023.103617_b0075","doi-asserted-by":"crossref","first-page":"e1006784","DOI":"10.1371\/journal.ppat.1006784","article-title":"The role of host DNA ligases in hepadnavirus covalently closed circular DNA formation","volume":"13","author":"Long","year":"2017","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.drudis.2023.103617_b0080","doi-asserted-by":"crossref","first-page":"e00922","DOI":"10.1128\/JVI.00922-20","article-title":"Characterization of the termini of cytoplasmic hepatitis B virus deproteinated relaxed circular DNA","volume":"95","author":"Cai","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2023.103617_b0085","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1128\/JVI.02020-06","article-title":"Enhancement of hepatitis B virus replication by the regulatory X protein in vitro and in vivo","volume":"81","author":"Keasler","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2023.103617_b0090","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1128\/JVI.79.7.4238-4245.2005","article-title":"Hepatitis B virus X protein stimulates viral genome replication via a DDB1-dependent pathway distinct from that leading to cell death","volume":"79","author":"Leupin","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2023.103617_b0095","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1128\/JVI.79.9.5548-5556.2005","article-title":"The transcriptional transactivation function of HBx protein is important for its augmentation role in hepatitis B virus replication","volume":"79","author":"Tang","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2023.103617_b0100","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jhep.2011.02.015","article-title":"Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection","volume":"55","author":"Lucifora","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2023.103617_b0105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev.pathol.1.110304.100230","article-title":"Immunobiology and pathogenesis of viral hepatitis","volume":"1","author":"Guidotti","year":"2006","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.drudis.2023.103617_b0110","doi-asserted-by":"crossref","first-page":"9849","DOI":"10.1073\/pnas.1730940100","article-title":"Nuclear import of hepatitis B virus capsids and release of the viral genome","volume":"100","author":"Rabe","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2023.103617_b0115","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.1128\/jvi.70.7.4269-4274.1996","article-title":"Hepatitis B virus nucleocapsid envelopment does not occur without genomic DNA synthesis","volume":"70","author":"Gerelsaikhan","year":"1996","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2023.103617_b0120","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3390\/v9060156","article-title":"The role of cccDNA in HBV maintenance","volume":"9","author":"Allweiss","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2023.103617_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104824","article-title":"Hepatitis B virus cccDNA: formation, regulation and therapeutic potential","volume":"180","author":"Xia","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2023.103617_b0130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.antiviral.2019.01.004","article-title":"Characterization of the molecular events of covalently closed circular DNA synthesis in de novo hepatitis B virus infection of human hepatoma cells","volume":"163","author":"Dezhbord","year":"2019","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2023.103617_b0135","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3748\/wjg.v13.i1.48","article-title":"Hepatitis B virus replication","volume":"13","author":"Beck","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.drudis.2023.103617_b0140","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jcmgh.2022.08.002","article-title":"cccDNA surrogate MC-HBV-based screen identifies cohesin complex as a novel HBV restriction factor","volume":"14","author":"Wu","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2023.103617_b0145","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bpg.2017.04.012","article-title":"Current treatment guidelines of chronic hepatitis B: the role of nucleos(t)ide analogues and peginterferon","volume":"31","author":"Ghany","year":"2017","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.drudis.2023.103617_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2014.04.005","article-title":"Nucleoside\/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance","volume":"8","author":"Men\u00e9ndez-Arias","year":"2014","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.drudis.2023.103617_b0155","doi-asserted-by":"crossref","first-page":"195","DOI":"10.14218\/JCTH.2019.00047","article-title":"HBV cccDNA: the stumbling block for treatment of HBV infection","volume":"7","author":"Liu","year":"2019","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.drudis.2023.103617_b0160","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/jama.2018.3795","article-title":"Chronic hepatitis B infection: a review","volume":"319","author":"Tang","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2023.103617_b0165","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/a-0824-1576","article-title":"Towards curative therapy of chronic viral hepatitis","volume":"57","author":"Bartenschlager","year":"2019","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.drudis.2023.103617_b0170","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.omtm.2020.11.014","article-title":"CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice","volume":"20","author":"Stone","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.drudis.2023.103617_b0175","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.3390\/v14122654","article-title":"Gene editing technologies to target HBV cccDNA","volume":"14","author":"Martinez","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2023.103617_b0180","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/hep.32245","article-title":"HBV covalently closed circular DNA minichromosomes in distinct epigenetic transcriptional states differ in their vulnerability to damage","volume":"75","author":"Wang","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2023.103617_b0185","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1096\/fj.201500134","article-title":"Reciprocal regulation of farnesoid X receptor \u03b1 activity and hepatitis B virus replication in differentiated HepaRG cells and primary human hepatocytes","volume":"30","author":"Radreau","year":"2016","journal-title":"FASEB J"},{"key":"10.1016\/j.drudis.2023.103617_b0190","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s11418-016-0980-6","article-title":"Epigallocatechin gallate inhibits hepatitis B virus via farnesoid X receptor alpha","volume":"70","author":"Xu","year":"2016","journal-title":"J Nat Med"},{"key":"10.1016\/j.drudis.2023.103617_b0195","doi-asserted-by":"crossref","first-page":"24066","DOI":"10.1021\/acsomega.2c02216","article-title":"HBV cccDNA \u2014 a culprit and stumbling block for the hepatitis B virus infection: its presence in hepatocytes perplexed the possible mission for a functional cure","volume":"7","author":"Bhat","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.drudis.2023.103617_b0200","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/jmcb\/mjz104","article-title":"An HBV-encoded miRNA activates innate immunity to restrict HBV replication","volume":"12","author":"Zhao","year":"2020","journal-title":"J Mol Cell Biol"},{"key":"10.1016\/j.drudis.2023.103617_b0205","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/mt.2013.31","article-title":"Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection","volume":"21","author":"Wooddell","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.drudis.2023.103617_b0210","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.drudis.2015.01.008","article-title":"Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA","volume":"20","author":"Ahmed","year":"2015","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2023.103617_b0215","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.jhep.2016.02.016","article-title":"New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus","volume":"64","author":"Durantel","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2023.103617_b0220","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1128\/AAC.00473-12","article-title":"Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation","volume":"56","author":"Cai","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2023.103617_b0225","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10620-017-4842-1","article-title":"Advanced strategies for eliminating the cccDNA of HBV","volume":"63","author":"Dong","year":"2018","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.drudis.2023.103617_b0230","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1128\/JVI.01921-09","article-title":"Production and function of the cytoplasmic deproteinized relaxed circular DNA of hepadnaviruses","volume":"84","author":"Guo","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2023.103617_b0235","doi-asserted-by":"crossref","first-page":"8000","DOI":"10.3748\/wjg.v19.i44.8000","article-title":"Identification and characterization of a novel bipartite nuclear localization signal in the hepatitis B virus polymerase","volume":"19","author":"Lupberger","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.drudis.2023.103617_b0240","doi-asserted-by":"crossref","first-page":"10938","DOI":"10.1021\/acs.jmedchem.1c02215","article-title":"Discovery of novel cccDNA reducers toward the cure of hepatitis B virus infection","volume":"65","author":"Chen","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2023.103617_b0245","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jhep.2022.12.014","article-title":"Discovery of a first-in-class orally available HBV cccDNA inhibitor","volume":"78","author":"Wang","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2023.103617_b0250","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1128\/jvi.66.7.4107-4116.1992","article-title":"The arginine-rich domain of the hepatitis B virus core protein is required for pregenome encapsidation and productive viral positive-strand DNA synthesis but not for virus assembly","volume":"66","author":"Nassal","year":"1992","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2023.103617_b0255","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1128\/JVI.01671-06","article-title":"Regulation of hepadnavirus reverse transcription by dynamic nucleocapsid phosphorylation","volume":"81","author":"Basagoudanavar","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2023.103617_b0260","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.jhep.2016.02.016","article-title":"New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus","volume":"64","author":"Durantel","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2023.103617_b0265","doi-asserted-by":"crossref","first-page":"42374","DOI":"10.1038\/srep42374","article-title":"Heteroaryldihydropyrimidine (HAP) and sulfamoylbenzamide (SBA) inhibit hepatitis B virus replication by different molecular mechanisms","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2023.103617_b0270","doi-asserted-by":"crossref","first-page":"e01440","DOI":"10.1128\/AAC.01440-19","article-title":"A new role for capsid assembly modulators to target mature hepatitis B virus capsids and prevent virus infection","volume":"64","author":"Ko","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2023.103617_b0275","doi-asserted-by":"crossref","first-page":"e1006658","DOI":"10.1371\/journal.ppat.1006658","article-title":"HBV core protein allosteric modulators differentially alter cccDNA biosynthesis from de novo infection and intracellular amplification pathways","volume":"13","author":"Guo","year":"2017","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.drudis.2023.103617_b0280","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.drudis.2023.103617_b0285","doi-asserted-by":"crossref","first-page":"8138","DOI":"10.1073\/pnas.0409732102","article-title":"A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly","volume":"102","author":"Stray","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2023.103617_b0290","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1128\/AAC.01091-13","article-title":"Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly","volume":"57","author":"Wu","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2023.103617_b0295","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0166-3542(01)00216-9","article-title":"Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model","volume":"54","author":"Weber","year":"2002","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2023.103617_b0300","doi-asserted-by":"crossref","first-page":"e1010204","DOI":"10.1371\/journal.ppat.1010204","article-title":"Bay41-4109-induced aberrant polymers of hepatitis B capsid proteins are removed via STUB1-promoted p62-mediated macroautophagy","volume":"18","author":"Lin","year":"2022","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.drudis.2023.103617_b0305","doi-asserted-by":"crossref","first-page":"e01686","DOI":"10.1128\/AAC.01686-19","article-title":"A first-in-human trial of GLS4, a novel inhibitor of hepatitis B virus capsid assembly, following single- and multiple-ascending-oral-dose studies with or without ritonavir in healthy adult volunteers","volume":"64","author":"Zhao","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2023.103617_b0310","doi-asserted-by":"crossref","first-page":"6931","DOI":"10.1128\/JVI.00582-13","article-title":"Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids","volume":"87","author":"Campagna","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2023.103617_b0315","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ejmech.2017.06.062","article-title":"Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector","volume":"138","author":"Sari","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2023.103617_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112714","article-title":"Discovery and optimization of benzenesulfonamides-based hepatitis B virus capsid modulators via contemporary medicinal chemistry strategies","volume":"206","author":"Ren","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2023.103617_b0325","first-page":"e01734","article-title":"Preclinical characterization of NVR 3\u2013778, a first-in-class capsid assembly modulator against hepatitis B virus","volume":"63","author":"Lam","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2023.103617_b0330","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1053\/j.gastro.2018.12.023","article-title":"Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3\u2013778 in patients with chronic HBV infection","volume":"156","author":"Yuen","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2023.103617_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103363","article-title":"Design, synthesis and anti-HBV activity of NVR3-778 derivatives","volume":"94","author":"Lv","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2023.103617_b0340","doi-asserted-by":"crossref","first-page":"e02439","DOI":"10.1128\/AAC.02439-19","article-title":"Antiviral properties and mechanism of action studies of the hepatitis B virus capsid assembly modulator JNJ-56136379","volume":"64","author":"Berke","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2023.103617_b0345","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1021\/acs.jmedchem.3c00173","article-title":"Discovery of linvencorvir (RG7907), a hepatitis B virus core protein allosteric modulator, for the treatment of chronic HBV infection","volume":"66","author":"Zhang","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2023.103617_b0350","first-page":"S248","article-title":"ABI-4334, a novel inhibitor of hepatitis B virus core protein, promotes formation of empty capsids and prevents covalently closed circular DNA formation by disruption of incoming capsids","volume":"76","author":"Unchwaniwala","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2023.103617_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104613","article-title":"an unexploited target for antiviral intervention against HIV and hepatitis B virus","volume":"171","author":"Tramontano","year":"2019","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2023.103617_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114760","article-title":"Current medicinal chemistry strategies in the discovery of novel HIV-1 ribonuclease H inhibitors","volume":"243","author":"Zhang","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2023.103617_b0365","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1021\/acsinfecdis.8b00045","article-title":"Chemical approaches to inhibiting the hepatitis B virus ribonuclease H","volume":"5","author":"Tavis","year":"2019","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.drudis.2023.103617_b0370","doi-asserted-by":"crossref","first-page":"e0146021","DOI":"10.1128\/AAC.01460-21","article-title":"Efficient inhibition of hepatitis B virus (HBV) replication and cccDNA formation by HBV ribonuclease H inhibitors during infection","volume":"65","author":"Chauhan","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2023.103617_b0375","doi-asserted-by":"crossref","first-page":"e1003125","DOI":"10.1371\/journal.ppat.1003125","article-title":"The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes","volume":"9","author":"Tavis","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.drudis.2023.103617_b0380","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3390\/v13071327","article-title":"Strategies to inhibit hepatitis B virus at the transcript level","volume":"13","author":"Qu","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2023.103617_b0385","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/jm034265a","article-title":"Synthesis and antiviral activity of helioxanthin analogues","volume":"48","author":"Yeo","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2023.103617_b0390","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3851\/IMP1686","article-title":"Helioxanthin analogue 8\u20131 inhibits duck hepatitis B virus replication in cell culture","volume":"21","author":"Ying","year":"2010","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.drudis.2023.103617_b0395","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.bmc.2009.12.038","article-title":"Synthesis and the biological evaluation of arylnaphthalene lignans as anti-hepatitis B virus agents","volume":"18","author":"Janmanchi","year":"2010","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2023.103617_b0400","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jep.2013.09.009","article-title":"Isolation and identification of an anti-hepatitis B virus compound from Hydrocotyle sibthorpioides Lam","volume":"150","author":"Huang","year":"2013","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.drudis.2023.103617_b0405","article-title":"Ciliatoside A, isolated from Peristrophe japonica, inhibits HBsAg expression and cccDNA transcription by inducing autophagy","volume":"209","author":"Fang","year":"2022","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2023.103617_b0410","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/jcmm.16137","article-title":"Neddylation inhibitor MLN4924 has anti-HBV activity via modulating the ERK-HNF1\u03b1-C\/EBP\u03b1-HNF4\u03b1 axis","volume":"25","author":"Xie","year":"2021","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.drudis.2023.103617_b0415","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/gutjnl-2020-322571","article-title":"Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5\/6 complex and silencing of the viral genome in vivo","volume":"71","author":"Allweiss","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.drudis.2023.103617_b0420","doi-asserted-by":"crossref","first-page":"19975","DOI":"10.1073\/pnas.0908365106","article-title":"Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function","volume":"106","author":"Belloni","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2023.103617_b0425","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1016\/j.celrep.2016.08.026","article-title":"Hepatitis B virus X protein promotes degradation of SMC5\/6 to enhance HBV replication","volume":"116","author":"Murphy","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.drudis.2023.103617_b0430","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.canlet.2010.06.003","article-title":"Activated Notch signaling is required for hepatitis B virus X protein to promote proliferation and survival of human hepatic cells","volume":"198","author":"Wang","year":"2010","journal-title":"Cancer Lett"},{"key":"10.1016\/j.drudis.2023.103617_b0435","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3892\/ijo.2015.3221","article-title":"Hepatitis B virus X protein activates Notch signaling by its effects on Notch1 and Notch4 in human hepatocellular carcinoma","volume":"48","author":"Gao","year":"2016","journal-title":"Int J Oncol"},{"key":"10.1016\/j.drudis.2023.103617_b0440","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1872-034X.2010.00680.x","article-title":"Blockage of Notch1 signaling modulates the T-helper (Th)1\/Th2 cell balance in chronic hepatitis B patients","volume":"10","author":"Pei","year":"2010","journal-title":"Hepatol Res"},{"key":"10.1016\/j.drudis.2023.103617_b0445","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/s41598-018-38139-5","article-title":"Notch signaling facilitates hepatitis B virus covalently closed circular DNA transcription via cAMP response element-binding protein with E3 ubiquitin ligase-modulation","volume":"9","author":"Wang","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2023.103617_b0450","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jhep.2011.02.015","article-title":"Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection","volume":"55","author":"Lucifora","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2023.103617_b0455","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.virol.2015.02.031","article-title":"Molecular biology of hepatitis B virus infection","volume":"479\u2013480","author":"Seeger","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.drudis.2023.103617_b0460","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jhep.2020.09.019","article-title":"Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx","volume":"74","author":"Cheng","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2023.103617_b0465","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.3390\/molecules27155000","article-title":"Identification of estradiol benzoate as an inhibitor of HBx using inducible stably transfected HepG2 cells expressing HiBiT tagged HBx","volume":"27","author":"He","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2023.103617_b0470","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jcmgh.2018.10.010","article-title":"Inhibition of HBV transcription from cccDNA with nitazoxanide by targeting the HBx-DDB1 interaction","volume":"7","author":"Sekiba","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2023.103617_b0475","doi-asserted-by":"crossref","first-page":"12015","DOI":"10.3390\/ijms231912015","article-title":"Antiviral compounds screening targeting HBx protein of the hepatitis B virus","volume":"23","author":"Ma","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2023.103617_b0480","doi-asserted-by":"crossref","first-page":"13851","DOI":"10.1021\/acs.jmedchem.0c01381","article-title":"Scalable synthesis, in vitro cccDNA reduction, and in vivo antihepatitis B virus activity of a phosphonomethoxydeoxythreosyl adenine prodrug","volume":"63","author":"Luo","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2023.103617_b0485","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat Rev Drug Discov"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644623001332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644623001332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:07:27Z","timestamp":1761224847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644623001332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":97,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1359644623001332"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2023.103617","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting hepatitis B virus cccDNA levels: Recent progress in seeking small molecule drug candidates","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2023.103617","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103617"}}